Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7976026 | 0.81 | KDM4E (0.35) | KDM4EHSD17B10LMNASCN10AHPGD | |
| SCHEMBL14511649 | 0.73 | MAPT (0.37) | KDM4EHSD17B10HPGDPOLBMAPT | |
| SCHEMBL19087003 | 0.72 | PDE2A (0.35) | KDM4EHSD17B10LMNAPDE2A | |
| SCHEMBL3787517 | 0.70 | KDM4E (0.35) | KDM4EHSD17B10LMNAHPGDALDH1A1 | |
| SCHEMBL17788668 | 0.69 | KDM4E (0.40) | KDM4EHSD17B10LMNAHPGDPOLB | |
| SCHEMBL22210589 | 0.69 | KDM4E (0.37) | KDM4EHSD17B10LMNASCN10APDE2A | |
| SCHEMBL798499 | 0.69 | KDM4E (0.34) | KDM4EHSD17B10LMNAHPGDALDH1A1 | |
| SCHEMBL21937453 | 0.66 | SCN10A (0.39) | KDM4EHSD17B10LMNASCN10APDE2A | |
| SCHEMBL22210591 | 0.65 | KDM4E (0.51) | KDM4EHSD17B10LMNASCN10AHPGD | |
| SCHEMBL17449485 | 0.65 | KDM4E (0.37) | KDM4EHSD17B10LMNASCN10APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | KDM4E 2506/4885HSD17B10 3403/4885LMNA 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.